Crossmark

A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer

Crossref DOI link: https://doi.org/10.1186/s40780-022-00261-y

Published Online: 2022-12-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Machida, Maiko https://orcid.org/0000-0002-3610-8916
Yamazaki, Chika

Kouda, Nao

Hanai, Yousei

Sato, Hideki

Konda, Ainari

Yamagata, Yuka

Itho, Tatsuya

Aisaka, Haruhiko
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (21K06648)
License Information

Text and Data Mining valid from 2022-12-05

Version of Record valid from 2022-12-05
More Information

Article History

Received: 24 August 2022

Accepted: 11 October 2022

First Online: 5 December 2022

Declarations

:

: This study (Research for early detection of adverse events of immune checkpoint inhibitors, UMIN000044022, registered 23 April 2021, ) was approved by the Ethics Committee of Hokkaido University of Science and Japan Community Health Care Organization Sapporo Hokushin Hospital. Informed consent was obtained from the patient.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below